Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$67.86 USD

67.86
5,625,845

-0.69 (-1.01%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $67.88 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (91 out of 245)

Industry: Medical - Dental Supplies

Zacks News

Zacks Equity Research

Charles River (CRL) to Offer Cryo-EM Capabilities With New Pact

Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.

Zacks Equity Research

Here's Why You Should Invest In Henry Schein (HSIC) Now

Investors continue to be optimistic about Henry Schein (HSIC) on its extensive global foothold and raised 2021 earnings guidance.

Zacks Equity Research

HSIC or CNMD: Which Is the Better Value Stock Right Now?

HSIC vs. CNMD: Which Stock Is the Better Value Option?

Zacks Equity Research

QIAGEN (QGEN) to Report Q3 Earnings: What's in the Cards?

New product approvals, partnerships in the diagnostic solutions category and sustained success in other product areas are likely to have contributed to QIAGEN's (QGEN) growth.

Zacks Equity Research

3 Reasons to Add Catalent (CTLT) Stock to Your Portfolio

Investors continue to be optimistic about Catalent (CTLT) owing to its slew of strategic deals and product launches.

Zacks Equity Research

Cardinal Health's (CAH) Unit Ties Up to Boost Diabetes Care

Cardinal Health's (CAH) company, OptiFreight Logistics', recent collaboration with Journey Biosciences to help patients with respect to long-term diabetes care.

Zacks Equity Research

Here's Why You Should Retain Cooper Companies (COO) Stock Now

Cooper Companies (COO) continues to benefit from strength in its business segments.

Zacks Equity Research

Allscripts' (MDRX) New AI-Based Offering to Improve Patient Care

Allscripts' (MDRX) latest AI-based scheduling application is expected to provide improved patient care as well as increase operational efficiencies of the healthcare system.

Zacks Equity Research

Quest Diagnostics (DGX) Enhances Lab Experience With Facility

Quest Diagnostics (DGX) new facility is fully operational and will empower better health for the patients and clients in the seven states the lab serves.

Zacks Equity Research

COVID Test Demand to Aid Quest Diagnostics (DGX) Q3 Earnings

In terms of strategic acquisitions, Quest Diagnostics (DGX) is likely to have secured high returns in Q3 from the acquisition of Mercy's outreach laboratory services business.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Zacks Equity Research

Henry Schein (HSIC) Dental Sales Grow Globally Despite Pandemic

Widespread network and channel mix along with favorable long-term trends in the dental business bode well for Henry Schein (HSIC).

Zacks Equity Research

Dexcom's (DXCM) G6 CGM System Gets Coverage in Manitoba

Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.

Zacks Equity Research

Reasons to Hold on to Inari Medical (NARI) Stock For Now

Investors continue to be optimistic about Inari Medical (NARI) owing to its focus on understanding the venous system and its commitment toward patient care.

Zacks Equity Research

Veeva Systems' (VEEV) Deal to Enhance Digital Clinical Trials

Veeva Systems' (VEEV) partnership with Leo Pharma to significantly boost the clinical trial process for patients, sites and sponsors.

Zacks Equity Research

Here's Why You Should Hold on to NextGen (NXGN) Stock Now

NextGen (NXGN) continues to gain momentum on the back of solid demand for its solutions and strength in EHR. However, intense competition woes linger.

Zacks Equity Research

LabCorp (LH) Gets FDA's EUA for Combined Home Collection Kit

The EUA for LabCorp's (LH) combined home collection kit can enable health-care providers to identify and treat individuals suspected of COVID-19 or influenza A/B infection.

Zacks Equity Research

Here's Why You Should Add Neogen (NEOG) to Your Portfolio Now

Investors are optimistic about Neogen (NEOG) on strength in its Food Safety and Animal Safety business segments.

Zacks Equity Research

Reasons to Hold on to Veeva Systems (VEEV) Stock For Now

Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of product launches and robust product adoptions.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock For Now

Investors are optimistic about CVS Health (CVS) on growth in the company's specialty digital solutions and a bullish 2021 outlook.

Zacks Equity Research

Here's Why You Should Invest in Patterson Companies (PDCO) Stock

Patterson Companies (PDCO) continues to benefit from strength in Animal Health business and dental business.

Zacks Equity Research

Cardinal Health's (CAH) Unit to Aid Canadian Healthcare System

Cardinal Health's (CAH) subsidiary to support the Canadian Healthcare system against COVID-19 with vaccination policy.

Zacks Equity Research

Veeva Systems' (VEEV) New Offering to Optimize Lab Operations

Veeva Systems' (VEEV) Vault LIMS is expected to help manufacturers optimize lab management and significantly simplify their systems landscape via a unified suite of quality and lab applications.

Zacks Equity Research

Here's Why You Should Invest in West Pharmaceutical (WST) Now

West Pharmaceutical (WST) continues to gain momentum on the back of strength in Proprietary Products business.

Zacks Equity Research

PacBio (PACB) Partners with ERGA, Boosts Biodiversity Research

PacBio's (PACB) collaboration with ERGA will help scientists to take the first important step toward creating high-quality genetic maps of each plant and animal species in a reliable manner.